2021 update of the GEFPICS' recommendations for HER2 status assessment in invasive breast cancer in France

被引：31

作者：

Franchet, Camille ^{[1
]}

Djerroudi, Lounes ^{[1
]}

Maran-Gonzalez, Aurelie ^{[1
]}

Abramovici, Olivia ^{[1
]}

Antoine, Martine ^{[1
]}

Becette, Veronique ^{[1
]}

Berghian, Anca ^{[1
]}

Blanc-Fournier, Cecile ^{[1
]}

Brabencova, Eva ^{[1
]}

Charafe-Jauffret, Emmanuelle ^{[1
]}

Chenard, Marie-Pierre ^{[1
]}

Dauplat, Marie-Melanie ^{[1
]}

Delree, Paul ^{[1
]}

Duprez-Paumier, Raphaelle ^{[1
]}

Fleury, Clemence ^{[1
]}

Ghnassia, Jean-Pierre ^{[1
]}

Haudebourg, Juliette ^{[1
]}

Leroux, Agnes ^{[1
]}

MacGrogan, Gaetan ^{[1
]}

Mathieu, Marie-Christine ^{[1
]}

Michenet, Patrick ^{[1
]}

Penault-Llorca, Frederique ^{[1
]}

Poulet, Bruno ^{[1
]}

Robin, Yves Marie ^{[1
]}

Roger, Pascal ^{[1
]}

Russ, Elisabeth ^{[1
]}

Tixier, Lucie ^{[1
]}

Treilleux, Isabelle ^{[1
]}

Valent, Alexander ^{[1
]}

Verriele, Veronique ^{[1
]}

Vincent-Salomon, Anne ^{[1
]}

Arnould, Laurent ^{[1
]}

Lacroix-Triki, Magali ^{[1
]}

机构：

[1] Grp Etud Facteurs Pronost Immunohistochim Canc Se, Unicanc, 101 Rue Tolbiac, F-75654 Paris 13, France

来源：

ANNALES DE PATHOLOGIE | 2021年 / 41卷 / 06期

关键词：

Breast cancer; Guidelines; HER2; Immunohistochemistry; In situ hybridization; ERBB2; PATHOLOGICAL COMPLETE RESPONSE; IN-SITU HYBRIDIZATION; FACTOR RECEPTOR 2; GENE AMPLIFICATION; ADJUVANT TRASTUZUMAB; ESTROGEN-RECEPTOR; OPEN-LABEL; MULTICENTER; EXPRESSION; MUTATIONS;

D O I：

10.1016/j.annpat.2021.07.014

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

The last international guidelines on HER2 determination in breast cancer have been updated in 2018 by the American Society of Clinical Oncology and College of American Pathologists, on the basis of a twenty-year practice and results of numerous clinical trials. Moreover, the emerging HER2-low concept for 1+ and 2+ non amplified breast cancers lead to refine French practices for HER2 status assessment. The GEFPICS group, composed of expert pathologists, herein presents the latest French recommendations for HER2 status evaluation in breast cancer, taking into account the ASCO/CAP guidelines and introducing the HER2-low concept. In the era of personalized medicine, HER2 status assessment remains one of the most important biomarkers in breast cancer and its quality guaranties the optimal patients' care. French pathologists' commitment in theranostic biomarker quality is more than ever required to provide the most efficient cares in oncology. (C) 2021 Elsevier Masson SAS. All rights reserved.

引用

页码：507 / 520

页数：14

共 50 条

[1] Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France
Penault-Llorca, Frederique
Vincent-Salomon, Anne
Bellocq, Jean-Pierre
Matthieu, Marie-Christine
Grogan, Gaetan-Mac
Treilleux, Isabelle
Ettore, Francette
Laberge-Le Couteulx, Sophie
Sigal, Brigitte
Couturier, Jerome
Lacroix-Triki, Magali
Antoine, Martine
Balaton, Andre
Baranzelli, Marie-Christine
Becette, Valerie
Blanc-Fournier, Cecile
Bibeau, Frederic
Brabencova, Eva
Croce, Sabrina
Fridman, Viviana
Genin, Pascal
Ghnassia, Jean-Pierre
Jacquemier, Jocelyne
Poulet, Bruno
Roger, Pascal
Sagan, Christine
Tas, Patrick
Trassard, Martine
Verriele, Veronique
Arnould, Laurent
ANNALES DE PATHOLOGIE, 2010, 30 (05) : 357 - 373
[2] 2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France
Penault-Llorca, Frederique
Vincent-Salomon, Anne
MacGrogan, Gaetan
Roger, Pascal
Treilleux, Isabelle
Valent, Alexander
Mathieu, Marie-Christine
Antoine, Martine
Becette, Veronique
Bor, Catherine
Brabencova, Eva
Charafe-Jauffret, Emmanuelle
Chenard, Marie-Pierre
Dauplat, Marie-Melanie
Delree, Paul
Devouassoux, Mojgan
Fiche, Maryse
Fondrevelle, Marie-Eve
Fridman, Viviana
Garbar, Christian
Genin, Pascal
Ghnassia, Jean-Pierre
Haudebourg, Juliette
Laberge-Le Couteulx, Sophie
Loussouarn, Delphine
Maran-Gonzalez, Aurelie
Marcy, Myriam
Michenet, Patrick
Poulet, Bruno
Sagan, Christine
Trassard, Martine
Verriele, Veronique
Arnould, Laurent
Lacroix-Triki, Magali
ANNALES DE PATHOLOGIE, 2014, 34 (05) : 352 - 365
[3] UPDATE OF THE RECOMMENDATIONS FOR HER2 STATUS DETERMINATION IN BREAST CANCERS: ASCO/CAP 2013 AND GEFPICS 2014.
Chahdi, H.
Allaoui, M.
Boudhas, A.
Tbouda, M.
El Ochi, M. R.
Damiri, A.
Al Bouzidi, A.
Oukabli, M.
JOURNAL OF MEDICAL AND SURGICAL RESEARCH, 2016, 3 (02): : 265 - 266
[4] UK recommendations for HER2 assessment in breast cancer: an update
Rakha, Emad A.
Tan, Puay Hoon
Quinn, Cecily
Provenzano, Elena
Shaaban, Abeer M.
Deb, Rahul
Callagy, Grace
Starczynski, Jane
Lee, Andrew H. S.
Ellis, Ian O.
Pinder, Sarah E.
JOURNAL OF CLINICAL PATHOLOGY, 2023, 76 (04) : 217 - 227
[5] Assessment of HER2 status in breast cancer
Penault-Llorca, F
Cayre, A
BULLETIN DU CANCER, 2004, 91 : S211 - S215
[6] Calibration of immunohistochemistry for assessment of HER2 in breast cancer:: results of the French Multicentre GEFPICS Study
Vincent-Salomon, A
MacGrogan, G
Couturier, J
Arnould, L
Denoux, Y
Fiche, M
Jacquemier, J
Mathieu, MC
Penault-Llorca, F
Rigaud, C
Roger, P
Treilleux, I
Vilain, MO
Mathoulin-Pélissier, S
Le Doussal, V
HISTOPATHOLOGY, 2003, 42 (04) : 337 - 347
[7] Automatization of HER2 Status Assessment in Breast Cancer
Makhov, Denis
Samorodov, Andrey
Slavnova, Elena
2019 URAL SYMPOSIUM ON BIOMEDICAL ENGINEERING, RADIOELECTRONICS AND INFORMATION TECHNOLOGY (USBEREIT), 2019, : 171 - 173
[8] Tumoral heterogeneity and HER2 status in invasive breast cancer
Asselah, J.
Cottu, P.
Vincent-Salomon, A.
Dieras, V
Mignot, L.
BULLETIN DU CANCER, 2007, 94 (06) : 568 - 568
[9] Tissue microarray technology in the routine assessment of HER2 status in invasive breast cancer
Cryan, Jane
O'Grady, Anthony
Allen, David
Kay, Elaine
HISTOPATHOLOGY, 2009, 54 (07) : 901 - 901
[10] Updated UK Recommendations for HER2 assessment in breast cancer
Rakha, Emad A.
Pinder, Sarah E.
Bartlett, John M. S.
Ibrahim, Merdol
Starczynski, Jane
Carder, Pauline J.
Provenzano, Elena
Hanby, Andrew
Hales, Sally
Lee, Andrew H. S.
Ellis, Ian O.
JOURNAL OF CLINICAL PATHOLOGY, 2015, 68 (02) : 93 - 99

← 1 2 3 4 5 →